Expanding Data Foundations to Unlock Predictivity & Regulatory Acceptance of NAMs

• Understand how model performance is limited by the training dataset and why incomplete or narrow data subsets lead to reduced predictivity and continued reliance on in vivo studies
• Learn practical approaches from pharma using integrated in vitro and in silico data for screening while ensuring IND-enabling decisions remain grounded in translatable evidence
• Explore collaboration strategies between toxicologists and AI scientists to generate scalable datasets and build models that support future first-in-human decision making

Speakers:

Mathew Martin

Executive Director, Global Head, Computational Safety Sciences

Pfizer